I’ll bet that no one else noticed this feature on Sokolove Law, LLC’s website?

Most of you probably know that I have been working on several new books about multiple myeloma. 

A few days back I ran a post about how improvements in the way allogeneic transplants are administered may help reduce the number and severity of side-effects:

The Myeloma Beacon’s Virginia Li wrote an interesting report late last week, highlighting how “more is not necessarily better” when it comes to myeloma therapy.

Amyloidosis is a close cousin to multiple myeloma.

Can’t a guy catch a break?

Interested in doing a bit of “light reading” this weekend?  Then don’t access the following three links I have been saving since November!

Of all the new combination drugs, the monoclonal antibody, elotuzumab, seems to excite myeloma experts most.

One year ago, a dear friend of mine passed-away after a long fight against multiple myeloma.  Ever notice how the myeloma usually wins?

Here is a link to an excellent Myeloma Beacon review/summary which compares different experimental proteasome inhibitors Marizomib (NPI-0052) and MLN9708 with Velcade and carfilzomib:

While it is a bit “after the fact,” it is exciting to learn this evening that the FDA has approved administering Velcade sub-q.

Saturday I had the opportunity to speak to a wonderful support group in Charlotte, NC.

I’m breathing a sigh of relief right now.

I wanted to share some excerpts from a sort of “year in review” interview with Dr. Deborah Dunsire, CEO of Millennium Pharmaceuticals, makers of Velcade.  I found this article on a site called Mass High Tech.com earlier this month:

Yesterday I asked if this secondary cancer issue “is much to do about nothing, or something that concerns you enough to keep you up at night?”

I haven’t written much about panobinostat , another new, combination drug lately.

Yesterday I set the stage for today’s report about research data which was featured at the International Myeloma Foundation’s Journalist Workshop Monday night.

Here is information about Millennium’s new, oral proteasome inhibitor, MLN9708.  Looks like they are making good progress…

Final results from the international, five year VISTA Velcade study were released yesterday at ASH.  Look this over and see what you think…

I know, I know.  I’m falling behind!  I’m so busy collecting and analyzing newly released myeloma related research data, I have barely had time to write.